2025年10月8日，诚益生物港股IPO申请获受理。该公司成立于2018年，是临床阶段的全球性生物技术公司，依托TRANDD平台研发新一代口服小分子药物。核心产品口服小分子GLP - 1受体激动剂ECC5004有望成同类最佳。财务上，2023年、2024年及2025年1 - 6月收入分别约3605.9万美元、2.21亿美元、55.7万美元。2023年底完成2500万美元C轮融资，投后估值4.98亿美元。其与阿斯利康合作，阿斯利康已付1.85亿美元预付款及6000万美元里程碑付款。国内超30家企业布局小分子GLP - 1产品。(AI生成)
责任编辑：小浪快报
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.